✦ LIBER ✦

Transdermal rivastigmine for Alzheimer’s disease: skin deep or scratching the surface?

✍ Scribed by A. J. Larner

Book ID: 111309241
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 131 KB
Volume: 64
Category: Article
ISSN: 1368-5031
DOI: 10.1111/j.1742-1241.2009.02305.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rivastigmine transdermal system for the

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease

✍ G. T. Grossberg; C. Sadowsky; J. T. Olin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Pharmacokinetics of a novel transdermal

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review

✍ A. Kurz; M. Farlow; G. Lefèvre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB

An open-labeled, multicentered, observat

An open-labeled, multicentered, observational study for the tolerability of Rivastigmine Transdermal Patch for Korean patients with Alzheimer's disease

✍ Hae Ri Na; Sangyun Kim; Dong-Won Yang; Moon Ho Park; Sang Seok Kim; Jung Seok Le 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Assessing the cost-effectiveness of the

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

✍ Balázs Nagy; Alan Brennan; Ágnes Brandtmüller; Simu K. Thomas; Sean D. Sullivan; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

Assess long-term cost-effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models based on clinical trial efficacy data. Methods: Incremental costs and Quality Adjusted Life Years (QALYs) associated with rivastigmine patch and capsule t